First immunotherapy on NHS for aggressive stomach cancer

18 May 2026

Getty/agrobacter

By Olivia Bowthorpe

The first immunotherapy for a form of aggressive stomach cancer will be available on the NHS after NICE recommended the treatment.

More than 1,500 patients a year with operable gastric and gastro-oesophageal junction cancers are expected to be eligible for durvalumab, which will be given with standard chemotherapy and surgery.







Log in or join for free to read more

You might also like